Rationale and Design of the Multicentre, Randomized, Double-Blind, Placebo-Controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) — Mihai Gheorghiade (2010) | RDL Network
Rationale and Design of the Multicentre, Randomized, Double-Blind, Placebo-Controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)
Article 2010 en
Authors
MG
Mihai Gheorghiade
MA
Mazen Albaghdadi
FZ
Faı̈ez Zannad
Abstract
1 min read
Aliskiren is a DRI with a favourable neurohormonal and haemodynamic profile that may benefit patients hospitalized with worsening HF. Given the neurohormonal abnormalities that are present during and after hospitalization for AHFS, it is hypothesized that adding aliskiren to standard therapy will reduce post-discharge mortality and re-hospitalization. NCT00894387.
Muthiah Vaduganathan, Baljash Cheema, Erin R. Cleveland, K. Nathan Sankar, Haris Subačius, Gregg C. Fonarow, Scott D. Solomon, Eldrin F. Lewis, Stephen J. Greene, Aldo Maggioni, Michael Böhm, Faı̈ez Zannad, Javed Butler, Mihai Gheorghiade
J. E. A. Blair, Peter S. Pang, Robert W. Schrier, Marco Metra, Brian Traver, Thomas D. Cook, Umberto Campia, Andrew P. Ambrosy, John C. Burnett, L. Grinfeld, Aldo Maggioni, Karl Swedberg, James E. Udelson, Faı̈ez Zannad, Marvin A. Konstam, Mihai Gheorghiade
Stephen J. Greene, Gregg C. Fonarow, Scott D. Solomon, Haris Subačius, Muthiah Vaduganathan, Andrew P. Ambrosy, Marat Fudim, Michael Böhm, Aldo Maggioni, Eldrin F. Lewis, Faı̈ez Zannad, Javed Butler
Muthiah Vaduganathan, Baljash Cheema, Erin R. Cleveland, K. Nathan Sankar, Haris Subačius, Gregg C. Fonarow, Scott D. Solomon, Eldrin F. Lewis, Stephen J. Greene, Aldo Maggioni, Michael Böhm, Faı̈ez Zannad, Javed Butler, Mihai Gheorghiade
Stephen J. Greene, Faı̈ez Zannad, Gregg C. Fonarow, Haris Subačius, Marco Triggiani, Andrew P. Ambrosy, Michael Böhm, Javed Butler, Ovidiu Chioncel, Aldo Maggioni, Scott D. Solomon, Muthiah Vaduganathan, Mihai Gheorghiade, Michele Senni
Discussion(0)
No comments yet. Be the first to comment.